NASDAQ · Biotechnology

Cogent Biosciences, Inc. (COGT) Stock

$30.08 -0.20% NASDAQ: COGT Healthcare

Valuation

MetricValue
Price$30.08
Market Cap$5.14B
P/E Ratio-13.36
P/B Ratio9.92
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$43.73
52-Week Low$13.78
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-72.57%
ROA-45.20%
ROCE-50.19%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.46
Current Ratio14.22

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-76.0M$-148.0M$-208.0M$-276.0M$-333.0M
Net Profit$-72.0M$-140.0M$-192.0M$-256.0M$-329.0M
EPS$-1.85$-2.26$-2.42$-2.32$-2.04
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$232.0M$301.0M$313.0M$328.0M$938.0M
Total Liabilities$18.0M$45.0M$56.0M$72.0M$301.0M
Cash$220.0M$140.0M$53.0M$98.0M$312.0M
Borrowings$3.0M$20.0M$19.0M$17.0M$253.0M

Latest News

Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib Insider Monkey · Jul 15, 2026 MEDevice Boston 2026: East Coast's Top Medical Device Conference Opens Registration for August 26-27 Event GlobeNewswire · Jul 6, 2026 Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment MT Newswires · Jun 30, 2026 Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) GlobeNewswire · Jun 30, 2026 Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market? Insider Monkey · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-59.0M$-119.0M$-154.0M$-208.0M$-264.0M
Investing Cash Flow$-3.0M$-132.0M$-101.0M$38.0M$-401.0M
Financing Cash Flow$0$2.0M$0$1.0M$-49.0M
Net Cash Flow$-23.0M$-80.0M$-88.0M$45.0M$214.0M
Free Cash Flow$-60.0M$-126.0M$-156.0M$-208.0M$-266.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.47
EV / EBITDA-14.32
FCF Yield-5.86%
Quick Ratio13.57
Interest Coverage-75.14
Return 1Y168.62%
Return 3Y171.56%
Return 5Y319.54%

Ownership

Insiders Held0.43%
Institutions Held112.94%
Institutions Float Held113.43%
Institutional HolderSharesReport Date
FMR, LLC23,122,7482026-03-31
Blackrock Inc.16,045,0142026-03-31
Deerfield Management Company, L.P9,043,9032026-03-31
Vanguard Portfolio Management LLC7,333,3332026-03-31
Vanguard Capital Management LLC6,894,9592026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVBPArriVent BioPharma, Inc. $16.71 -1.07% -7.60 $778.27M 0.00%
IDYAIDEAYA Biosciences, Inc. $36.06 -0.01% -19.46 $3.43B 0.00%
INCYIncyte Corporation $112.58 -0.15% 15.15 $22.82B 0.00%
KURAKura Oncology, Inc. $10.52 -1.41% -3.16 $933.91M 0.00%
MAZEMaze Therapeutics, Inc. $26.31 +1.66% -9.65 $1.46B 0.00%

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is led by CEO Andrew R. Robbins, employs 258 people, headquartered in Waltham, US, publicly traded since 2018.

Cogent Biosciences, Inc. (COGT) stock trades at $30.08 with a market capitalization of $5.14B. The stock is valued at a price-to-earnings (P/E) ratio of -13.36, price-to-book of 9.92, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $13.78 and $43.73, and currently trades 31.2% below its 52-week high.

On profitability, Cogent Biosciences, Inc. generates a return on equity (ROE) of -72.57%, return on capital employed of -50.19%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1173.89 +0.37% JNJ Johnson & Johnson $259.05 +1.00% ABBV AbbVie Inc. $275.98 +1.30% MRK Merck & Company, Inc. Common Stock (new) $144.69 +1.62% UNH UnitedHealth Group Incorporated Common Stock (DE) $375.98 +1.36% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $654.67 +0.41% AMGN Amgen Inc. $412.50 +1.24% GILD Gilead Sciences, Inc. $149.51 +1.64% ABT Abbott Laboratories $99.93 +1.46% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides